Janssen Research & Development, LLC
The purpose of the study is to assess what drug does to body when healthy Chinese participants receive single oral dose of JNJ-77242113.
Healthy
JNJ-77242113
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 30 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants |
Actual Study Start Date : | February 14, 2023 |
Estimated Primary Completion Date : | April 7, 2023 |
Estimated Study Completion Date : | April 12, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1: JNJ-77242113 Dose 1 Participants will receive a single oral dose of JNJ-77242113 Dose 1 on Day 1. |
Drug: JNJ-77242113 |
Experimental: Cohort 2: JNJ-77242113 Dose 2 Participants will receive a single oral dose of JNJ-77242113 Dose 2 on Day 1. |
Drug: JNJ-77242113 |
Experimental: Cohort 3: JNJ-77242113 Dose 3 Participants will receive a single oral dose of JNJ-77242113 Dose 3 on Day 1. |
Drug: JNJ-77242113 |
Ages Eligible for Study: | 18 Years to 55 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Peking University Third Hospital
Beijing, China, 100089